Biblio

Author Title [ Type

] Year

Filters: Author is Plütschow, Annette [Clear All Filters]

Journal Article

Sasse S, Bröckelmann PJan, Momotow J, Plütschow A, Hüttmann A, Basara N, Koenecke C, Martin S, Bentz M, Grosse-Thie C, et al. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma. 2022:1-8.

Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, et al. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol. 2021;8(4):e278-e288.

Grund J, Iben K, Reinke S, Bühnen I, Plütschow A, Müller-Meinhard B, Marquez MAGarcia, Schlößer HA, von Tresckow B, Kellermeier F, et al. Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma. Br J Haematol. 2023.

Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223-234.

Eichenauer DA, Bühnen I, Plütschow A, Kobe C, Dietlein M, Wendtner C-M, Thorspecken S, Topp MS, Mauser M, von Tresckow B, et al. Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Hematol Oncol. 2022.